Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 10 Parkinson's papers of 7,809 | 0.69 |
| pathways Reactome | 5 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 4653
Sealed predictions
- OTC in dopamine neurons, braak+0.48 (p 0.188) → +0.00 (p 1.000)receipt 4661
Swarm cases
receipt 4661: OTC in dopamine neurons, braak
- power
- full sample +0.19 (p 0.455, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.29 (p 0.243, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.281, n 18). could be the mix.
- skeptic
- leave-one-out range +0.07 to +0.32, sign flips 0; without severely affected donors +0.19 (p 0.455, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OTC in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts